Higher Levels of GATA3 Predict Better Survival in Women with Breast Cancer.
Dejun Shen, Nam K Yoon, Erin L Maresh, Yahya Elshimali, Sophia Apple, Steve Horvath, Vei Mah, Shikha Bose, David Chia, Helena R Chang, Lee Goodglick. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; UCLA David Geffen School of Medicine, Los Angeles, CA; Cedars Sinai Medical Center, Los Angeles, CA
Background: The GATA family members are zinc finger transcription factors involved in cell differentiation and proliferation. GATA3 in particular is necessary for mammary gland maturation, and its loss has been implicated in breast cancer development.
Design: Our goal was to validate the ability of GATA3 expression to predict survival in breast cancer patients. Protein expression of GATA3 was analyzed on a high density tissue microarray consisting of 242 cases of breast cancer. We associated GATA3 expression with patient outcomes and clinicopathological variables.
Results: Expression of GATA3 was significantly increased in breast cancer, in situ lesions, and hyperplastic tissue compared to normal breast tissue. GATA3 expression decreased with increasing tumor grade. Low GATA3 expression was a significant predictor of disease-related death in all patients, as well as in subgroups of estrogen receptor positive or low grade patients. Additionally, low GATA3 expression correlated with increased tumor size and estrogen and progesterone receptor negativity.
Conclusions: GATA3 is an important predictor of disease outcome in breast cancer patients. This finding has been validated in a diverse set of populations. Thus, GATA3 expression has utility as a prognostic indicator in breast cancer.
Wednesday, March 2, 2011 1:00 PM
Poster Session VI # 16, Wednesday Afternoon